SEATTLE, WA--(Marketwire - July 10, 2008) - Targeted Genetics Corporation (NASDAQ: TGEN) announced today that the Department of Defense Amyotrophic Lateral Sclerosis Research Program of the Office of the Congressionally Directed Medical Research Programs has recommended grant funding to Targeted Genetics of up to $2.4 million, to be applied towards preclinical development of new therapies for amyotrophic lateral sclerosis (ALS).
